Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders

NCT03301168 is registered in ClinicalTrials.gov with Bellicum Pharmaceuticals as lead sponsor.

NCT NCT03301168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03301168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Lead sponsor
Bellicum Pharmaceuticals
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 30, 2014
Completion date
May 31, 2034
Enrollment
120 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, anemia, aplastic, cytopenia, hemoglobinopathy in children, leukemia, acute myeloid (aml), child, lymphoma, non-hodgkin, myelodysplastic syndromes, osteopetrosis, primary immune deficiency disorder